Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant aspirin and/or metformin with induction chemotherapy and chemoradiotherapy for locally advanced rectal cancer
2018-004385-34Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aspirin and metformin in rectal cancer and rectal adenocarcinoma (4 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Good Pathological Response. Started Oct 2020; status: active.
02
Drugs
aspirinmetformin
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on 2018-004385-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004385-34.